secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0000950170-25-083830
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences appoints new CFO; shareholders approve stock plan share increases
--------------------------------------------------------------------------------

- Jeanette M. Bjorkquist appointed principal financial officer effective June 5, 2025; Jason A. Okazaki remains CEO.
- Shareholders approved Amendment No. 1 to 2018 Stock Incentive Plan: shares reserved increased by 375,000 to 1,478,333.
- Amendment No. 2 approved: 225,000 additional shares for performance-based vesting retention grants.
- ESPP Amendment No. 1 approved: shares reserved increased from 164,500 to 225,000.
- All 10 director nominees elected; Ernst & Young ratified as auditor for FY 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017025083830/0000950170-25-083830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017025083830/asmb-20250605.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-083830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer